Rosmantuzumab - OncoMed Pharmaceuticals

Drug Profile

Rosmantuzumab - OncoMed Pharmaceuticals

Alternative Names: Anti-RSPO3 antibody – Oncomed; Anti-RSPO3 – Oncomed; OMP-131R10; Rosmantuzumab

Latest Information Update: 09 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OncoMed Pharmaceuticals
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action RSPO3 protein inhibitors; Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer; Solid tumours

Most Recent Events

  • 04 Jan 2018 OncoMed Pharmaceuticals completes enrolment in its phase Ia/b trial for Colorectal cancer and Solid tumours in USA (IV) (NCT02482441)
  • 05 Apr 2017 Pharmacodynamics data from a preclinical trial in Colorectal cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2017)
  • 29 Nov 2016 Interim safety, efficacy and pharmacokinetics results presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top